Education
About Us
Working with TipRanks
Follow Us
Pelthos Therapeutics (PTHS)
:PTHS
PTHS Stock Chart & Stats
$25.10
--
Market closed
$25.10
--
Day’s Range― - ―
52-Week Range$8.11 - $54.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.94K
Market Cap
$77.48M
Enterprise Value$74.95M
Total Cash (Recent Filing)$14.25M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)―
Beta1.82
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,086,681
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-2.55
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue10.12
Enterprise Value/Gross Profit18.63
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$59.80Price Target Upside138.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Access And Product AdoptionStrong early commercial uptake of Zelsuvmi combined with favorable Medicaid formulary placements increases treatment accessibility and supports higher prescription volumes.
Product Portfolio ExpansionAcquisition of worldwide rights to an FDA‑approved single‑application head lice therapy (Xeglyze) broadens the commercial portfolio, leverages existing infrastructure, and adds a product that does not require ongoing payments to the seller.
Sales Force ExpansionPlanned expansion of the sales force to reach a substantially larger number of healthcare targets should widen market reach and help convert demand into sustained prescription growth.
Bears Say
Commercial And Reimbursement RiskChallenges in commercial execution and variability in payer reimbursement could limit product uptake and reduce expected revenue momentum.
Competitive ThreatVerrica’s FDA‑approved molluscum product Ycanth poses a direct competitive threat with a different application approach and a cost structure that could pressure market share for Zelsuvmi.
Regulatory, Intellectual Property And Financing RiskUncertainty around regulatory outcomes, potential intellectual property disputes, and the need for additional financing represent cross‑cutting risks that could impede growth plans.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $8.11 and its highest was $54.29 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $77.48M.
When is Pelthos Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pelthos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,086,681 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.80 (138.25% Upside)
$59.80 (138.25% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $280.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5808.39%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
PTHS Earnings Call
Q3 2025
0:00 / 0:00
PTHS Stock 12 Month Forecast
Average Price Target
$59.80
▲(138.25% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―